갑상선암의 핵의학 영상

키워드

참고문헌 (47)

1. Sawin CT, "Radioiodine and the treatment of hyperthyroidism: The early history", Thyroid, 7(2), pp.163~176 (1997)
2. Keston AS, "Storage of radioactive iodine in a metastasis from thyroid carcinoma", Science, 95(2466), pp.362~363 (1942)
3. Cooper DS, "Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
4. Boughattas S, "Preoperative scintigraphic visualization of lymph nodes and pulmonary metastases from papillary thyroid carcinoma", Ann Nucl Med, 18(1), pp.59~62 (2004)
5. 이주령, "분화 갑상선암 환자의 수술후 잔여갑상선조직 및 전이병소의 진단: Tc-99m Pertechnetate 스캔과 고용량 옥소 치료 후 I-131 스캔의 비교", Nuclear Medicine and Molecular Imaging, 37(2), pp.120~127 (2003), 대한핵의학회
6. Rosenberg IN, "Evaluation of thyroid function", N Engl J Med, 286(17), pp.924~927 (1972)
7. Sherman SI, "Thyroid carcinoma", Lancet, 361(9356), pp.501~511 (2003)
8. Yi KH, "Revised Korean thyroid association management guidelines for patients with thyroid nodules and thyroid cancer", J Korean Thyroid Assoc, 3(2), pp.65~96 (2010)
9. Muratet JP, "Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma", J Nucl Med, 38(9), pp.1362~1368 (1997)
10. Mazzaferri EL, "A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma", J Clin Endocrinol Metab, 88(4), pp.1433~1441 (2003)
11. Shankar LK, "Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer", J Nucl Med, 43(1), pp.72~76 (2002)
12. 이홍제, "분화 갑상선암의 추적 관찰에서 진단적 I-123 전신 스캔의 최적 영상 시점: 동일 환자에서 6시간과 24시간 영상의 비교", Nuclear Medicine and Molecular Imaging, 43(2), pp.129~136 (2009), 대한핵의학회
13. Mazzaferri EL, "Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer", J Clin Endocrinol Metab, 86(4), pp.1447~1463 (2001)
14. Pacini F, "Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels", J Nucl Med, 28(12), pp.1888~1891 (1987)
15. Schlumberger M, "131I therapy for elevated thyroglobulin levels", Thyroid, 7(2), pp.273~276 (1997)
16. Fatourechi V, "Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?", Thyroid, 10(7), pp.573~577 (2000)
17. Sherman SI, "Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma", J Clin Endocrinol Metab, 78(3), pp.629~634 (1994)
18. Souza Rosário PW, "Post I-131 therapy scanning in patients with thyroid carcinoma metastases: An unnecessary cost or a relevant contribution?", Clin Nucl Med, 29(12), pp.795~798 (2004)
19. Kogai T, "Differential regulation of the human sodium", iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells, 2001, pp.142(8), 3369~3379
20. Chung JK, "Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma", J Nucl Med, 38(8), pp.1191~1195 (1997)
21. Kucuk ON, "Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: Results in patients with lung metastases from differentiated thyroid cancer", Nucl Med Commun, 27(3), pp.261~266 (2006)
22. Hindié E, "Functioning pulmonary metastases of thyroid cancer: Does radioiodine influence the prognosis?", Eur J Nucl Med Mol Imaging, 30(7), pp.974~981 (2003)
23. Buck AK, "SPECT", CT, 2008, pp.49(8), 1305~1319
24. Tharp K, "Impact of 131I-SPECT", CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma, 2004, pp.31(10), 1435~1442
25. Shapiro B, "Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer", Semin Nucl Med, 30(2), pp.115~132 (2000)
26. Haveman JW, "Implications of mediastinal uptake of 131I with regard to surgery in patients with differentiated thyroid carcinoma", Cancer, 103(1), pp.59~67 (2005)
27. Wong KK, "Incremental value of diagnostic 131I SPECT", CT fusion imaging in the evaluation of differentiated thyroid carcinoma, 2008, pp.191(6), 1785~1794
28. Chen L, "Incremental value of 131I SPECT", CT in the management of patients with differentiated thyroid carcinoma, 2008, pp.49(12), 1952~1957
29. Spanu A, "131I SPECT", CT in the follow-up of differentiated thyroid carcinoma: Incremental value versus planar imaging, 2009, pp.50(2), 184~190
30. Schmidt D, "Impact of 131I SPECT", spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation, 2009, pp.50(1), 18~23
31. Patel CN, "Clinical utility of hybrid SPECT-CT in endocrine neoplasia", AJR Am J Roentgenol, 190(3), pp.815~824 (2008)
32. Lind P, "The use of non-specific tracers in the follow up of differentiated thyroid cancer: Results with Tc-99m tetrofosmin whole body scintigraphy", Acta Med Austriaca, 23(1), pp.69~75 (1996)
33. Wu HS, "Technetium-99m tetrofosmin single photon emissioncomputed tomography to detect metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan", Clin Radiol, 58(10), pp.787~790 (2003)
34. Lind P, "Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma", J Nucl Med, 38(3), pp.348~352 (1997)
35. Kucuk NO, "Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results", Ann Nucl Med, 20(6), pp.393~397 (2006)
36. Ng DC, "99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma", J Nucl Med, 41(4), pp.631~635 (2000)
37. Vattimo A, "Identification of Hürthle cell tumor by single-injection, double-phase scintigraphy with technetium- 99m-sestamibi", J Nucl Med, 36(5), pp.778~782 (1995)
38. Aktolun C, "Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors. Preliminary results and comparison with Tl-201", Clin Nucl Med, 17(3), pp.171~176 (1992)
39. Feine U, "Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer", Eur J Endocrinol, 138(5), pp.492~496 (1998)
40. Chin BB, "Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in welldifferentiated thyroid carcinoma", J Clin Endocrinol Metab, 89(1), pp.91~95 (2004)
41. Seo JH, "Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using 18F-FDG PET", CT, 201004, pp.72(4), 558~563[DOI]
42. Phan HT, "The diagnostic value of 124I-PET in patients with differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 35(5), pp.958~965 (2008)
43. Capoccetti F, "The effectiveness of 124I PET", CT in patients with differentiated thyroid cancer, 2009, pp.53(5), 536~545
44. Jentzen W, "Pre-therapeutic (124)I PET(", CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer, 2010, pp.37(5), 884~895
45. Freudenberg LS, "Value of (124)I-PET", CT in staging of patients with differentiated thyroid cancer, 2004, pp.14(11), 2092~2098
46. Freudenberg LS, "Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: Role of 124I-PET", CT and FDG-PET, 2008, pp.35(5), 950~957
47. tetrafluoroborate: A PET imaging agent for thyroid disease and reporter gene imaging of the sodium, "iodide symporter", Eur J Nucl Med Mol Imaging, 37(11), pp.2108~2116 (2010)

관련 논문AI추천